



ASX and Media Release

CAVATAK activity across multiple cancers presented at international oncolytic virus conference

17 June 2013, Sydney, Australia: Viralytics Limited (ASX:VLA, OTC:VRACY) is pleased to announce that three new pre-clinical research projects focussing on the positive activity of CAVATAK™ (CVA21) in Leukaemia, Lung cancer and Melanoma will be presented at the "The Seventh International Meeting on Replicating Oncolytic Virus Therapeutics" Quebec, Canada, 15-18 June 2013.

The three presentations are entitled:

- (i) Investigation of Potential Oncolytic Effects of Replication-Competent Coxsackievirus A21 (CVA21) in Combination with Chemotherapy on Various Lung Carcinomas*
- (ii) Combinatory Effects of Docetaxel with the Naturally Occurring Oncolytic Virus Coxsackievirus A21 (CVA21)*
- (iii) Coxsackievirus A21 (CVA21): Immune Cell Interactions and Oncolytic Activity in Leukaemia*

The first two posters, presented respectively by Viralytics' research team members Yvonne Vern Yee and Min Quah, will focus on the synergistic activity between CAVATAK™ and the commonly used chemotherapeutic agent docetaxel in pre-clinical models of both human lung cancer and melanoma.

The third poster will be presented by Professor Alan Melcher from the Leeds Institute of Cancer and Pathology, St James's University Hospital, Leeds, UK. This pre-clinical research identified potent anticancer activity of CAVATAK™ in chronic lymphocytic leukaemia (CLL) cells. CLL is the second most common type of leukaemia in adults in the USA.

All presentations are available on the Viralytics website.

"The attractive findings presented from these new pre-clinical research studies, in addition to the clinical activity that has been well publicised in melanoma patients, confirms the broad anti-cancer potency of CAVATAK™. The increased activity of a combination of CAVATAK™ and docetaxel provide further evidence for the potential use of this regimen in significant cancer indications such as lung cancer," said Dr Darren Shafren, Viralytics Chief Scientific Officer.

For personal use only



Enquiries:
Dr Malcolm McColl
02 9988 4000

Rudi Michelson
Monsoon Communications
03 9620 3333

About Viralytics Ltd:

Viralytics is developing oncolytic virotherapy treatments for a range of cancers. Viralytics' lead product, CAVATAK™, is a proprietary formulation of the common cold Coxsackievirus Type A21 (CVA21). CVA21 binds to specific 'receptor' proteins highly expressed on multiple cancer types including, but not limited to: melanoma; prostate, lung, breast and bladder cancers; and multiple myeloma. CAVATAK™ acts to kill both local and metastatic cancer cells, by direct cytolysis and a possible immune response. The preferential targeting of cancer rather than healthy cells provides the potential for low toxicity in the patient. The company is actively enrolling a phase II clinical trial, of intratumourally administered CAVATAK™ in the treatment of Late stage Melanoma (the CALM study), at multiple prestigious cancer clinics in the US. Viralytics plans to commence a Phase I/II trial of CAVATAK™ being delivered systemically (intravenously). This trial referred to as the STORM (Systemic Treatment Of Resistant Malignancies) study will be undertaken in patients with melanoma, prostate, lung or metastatic bladder cancers. The second stage of the STORM trial will include combination treatments with existing chemotherapies in one of the above cancer types. Subject to regulatory approval the STORM trial will commence at three prominent UK sites later in 2013.

Based in Sydney Australia, the company is listed on the Australian Securities Exchange (ASX: VLA) while Viralytics' ADRs also trade under VRACY on the US OTC market.

For personal use only